ストックスクリーナーアプリを入手
1.78
9.20%
0.15
プレマーケット:
1.65
-0.13
-7.30%
前日終値:
$1.63
開ける：
$1.63
24時間の取引高:
172.80K
Relative Volume:
1.50
時価総額：
$49.91M
収益：
-
当期純損益:
$-49.87M
株価収益率:
-0.9063
EPS:
-1.964
ネットキャッシュフロー:
$-19.36M
1週間 パフォーマンス:
+13.38%
1か月 パフォーマンス:
+36.92%
6か月 パフォーマンス:
+36.92%
1年 パフォーマンス:
+3.49%
1日の値動き範囲:
$1.555
$1.83
1週間の範囲:
$1.42
$1.83
52週間の値動き範囲:
$1.02
$2.40
Rein Therapeutics Inc Stock (RNTX) Company Profile
Compare RNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.78 | 45.70M | 0 | -49.87M | -19.36M | -1.964 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-22 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2017-07-24 | 開始されました | BofA/Merrill | Buy |
| 2017-07-24 | 開始されました | Jefferies | Buy |
| 2017-07-24 | 開始されました | William Blair | Outperform |
Rein Therapeutics Inc (RNTX) 最新ニュース
Why Rein Therapeutics Inc. stock is a must watch in 20262026 Earnings Surprises & Stock Timing and Entry Methods - bollywoodhelpline.com
FY2026 EPS Estimate for Rein Therapeutics Lowered by Analyst - defenseworld.net
PTN PE Ratio & Valuation, Is PTN Overvalued - Intellectia AI
RNTX Forecast, Price Target & Analyst Ratings | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
Stock List: Research Stocks from Around the World - GuruFocus
BLRX PE Ratio & Valuation, Is BLRX Overvalued - Intellectia AI
RNTX Should I Buy - Intellectia AI
Rein 2026 10-K Report: Business Overview, Risk Factors, Pipeline, Competition, and Strategic Partnerships - Minichart
Rein Therapeutics 10-K: $0 Revenue, $0 Gross Profit; Net Loss $49.9M - TradingView — Track All Markets
Rein Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Rein Therapeutics (NASDAQ: RNTX) 10-K shifts focus to LTI-03 and flags 2026 funding needs - stocktitan.net
Rein Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Rein Therapeutics Inc. (RNTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Decliners: What makes Rein Therapeutics Inc stock attractive today2026 Analyst Calls & High Accuracy Swing Trade Signals - baoquankhu1.vn
Risk Off: Can Rein Therapeutics Inc beat the S P 5002026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Update Recap: Can Rein Therapeutics Inc sustain earnings growthEarnings Trend Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Returns Recap: Can RenovoRx Inc expand its profit margins2026 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Will Rein Therapeutics Inc. stock outperform international peersPortfolio Performance Summary & Daily Chart Pattern Signal Reports - Naître et grandir
What technical signals suggest for IDAI stockBond Market & Daily Stock Trend Watchlist - Naître et grandir
How Roundhill ETF Trust Roundhill AMZN stock valuation compares with sector2025 Sector Review & Long-Term Safe Investment Plans - Naître et grandir
Why BILL stock appeals to dividend investorsJuly 2025 Recap & AI Powered Market Entry Strategies - Naître et grandir
Rein Therapeutics Secures Funding and Advances Key Clinical Trial () - aktiencheck.de
With FDA hold lifted, IPF clinical trial of LTI-03 begins dosing patients - Pulmonary Fibrosis News
Rein Therapeutics doses first patient in IPF trial for LTI-03 - Investing.com Canada
Rein Therapeutics doses first patient in phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis - marketscreener.com
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - GlobeNewswire
Rein Therapeutics Raises $2.3 Million in Private Unsecured Notes With 20% OID, Due by Jun 30, 2026 - TradingView
Chet Holmgren x Nike KD 18 "Thunder & Reign" Releases March 13th - Sneaker Bar Detroit
RNTX Technical Analysis & Stock Price Forecast - Intellectia AI
Rein Therapeutics Inc. announced that it has received $2.3 million in funding - marketscreener.com
White House to host Big Tech after pledge to rein in power costs - Yahoo Finance
Profit Recap: What are the future prospects of Sage Therapeutics Inc2025 Analyst Calls & Daily Entry Point Trade Alerts - baoquankhu1.vn
Rein Therapeutics Inc. announced that it expects to receive $2.3 million in funding - marketscreener.com
Targets Report: What makes Rein Therapeutics Inc stock attractive today2025 Technical Patterns & Smart Swing Trading Alerts - baoquankhu1.vn
Rein Therapeutics Announces Immediate Board Director Resignation - TipRanks
Rein Therapeutics (RNTX) director Aivado resigns from board role - Stock Titan
Quarterly Recap: How cyclical is The Nassau Companies of New York Preferred Securitys revenue streamEntry Point & Growth Oriented Trade Recommendations - baoquankhu1.vn
Rein Therapeutics Inc. Announces Manuel C. Alves Aivado Decides to Resign as Member of Board of Directors, Effective February 16, 2026 - marketscreener.com
Will Rein Therapeutics Inc. stock split again soon2025 Support & Resistance & Consistent Profit Trading Strategies - mfd.ru
Is Meteoric Resources NL (RNF) stock a buy for dividend portfoliosLayoff News & Verified Momentum Watchlists - mfd.ru
Stock Report: How correlated is Madrigal Pharmaceuticals Inc to the S P500Weekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Why Sterling Infrastructure Inc. (UAO) stock appeals to dividend investors2025 Market Outlook & Free Fast Entry Momentum Trade Alerts - mfd.ru
Is Rein Therapeutics Inc. stock oversold or undervalued2025 Price Action Summary & Daily Stock Trend Watchlist - mfd.ru
RNTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Por - GuruFocus
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - The Manila Times
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire
Buy Signal: What is Sotera Health Companys valuation compared to sectorJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
Rein Therapeutics (RNTX) Price Target Increased by 25.00% to 10.20 - Nasdaq
Aug Sentiment: Is Rein Therapeutics Inc a speculative investmentJuly 2025 Chart Watch & Proven Capital Preservation Methods - baoquankhu1.vn
Rein Therapeutics Inc (RNTX) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):